Immune System's "Barrier" to IgA2 Antibodies May Explain Vaccine Vulnerability to Breakthrough Infections
New research reveals a consistent obstacle in the immune response to mRNA vaccines, offering a potential explanation for why vaccinated individuals can still contract and transmit respiratory viruses.
Key Findings
- A Consistent Roadblock: Researchers identified a specific barrier in the process of antibody class switching that prevents the immune system from effectively producing IgA2 antibodies. These antibodies are crucial for protecting mucosal surfaces—like the nose and throat—against respiratory viruses.
- Detailed Study Profile: The study monitored 15 healthy adults with no prior SARS-CoV-2 exposure who received two doses of the Moderna mRNA-1273 vaccine. Blood samples were collected frequently over 12 weeks and again at six months to track the immune response in granular detail.
- Stepwise Halting Mechanism: Analysis of nearly 3.8 million antibody gene sequences, combined with single-cell analysis of B cells, revealed that class switch recombination proceeds in a strict, stepwise path. This process consistently halts at the IGHG2 gene, effectively blocking the final step required to switch to IgA2.
- Strong IgG1, Weak IgA2 Response: While the mRNA vaccine generated a robust IgG1 antibody response, it produced a very weak IgA2 response. This imbalance may explain why vaccinated individuals remain susceptible to infection and can still transmit the virus.
- Rethink of Immune Timing: The study challenges the long-held assumption that class switching and antibody refinement (somatic hypermutation) occur in parallel. Class switching happened rapidly in the early weeks, but the fine-tuning of antibodies was not detectable until six months later.
- Expansion of Atypical Cells: Following the second vaccine dose, "double negative" (DN) B cell subtypes expanded substantially among antigen-specific B cells. These DN cells are typically associated with chronic infections and autoimmune conditions, suggesting a novel immune pathway activated by the mRNA platform.
Expert Statements
Professor Deborah Dunn-Walters (University of Surrey):
"The consistency and precision of the barrier at IGHG2 in a first-time human response is new. The findings change our understanding of what the immune system can and cannot do when encountering a vaccine for the first time. The next question is whether vaccines can be designed to push past that barrier."
Professor Franca Fraternali (UCL):
"The separation between early class switching and late antibody refinement suggests important implications for vaccine booster timing."
Professor Claudia Mauri (UCL):
"Non-traditional B cells may be favored by the mRNA platform, which triggers an interferon signal that bypasses germinal centers where antibodies are normally refined."
Data Availability
The comprehensive dataset—which combines bulk and single-cell gene sequencing, flow cytometry, and serology from over 20 timepoints per participant—has been made publicly available for further research.